Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2118 August 2025

APPLICANT (stamp or sticker acceptable)		PATIENT NHI:	REFERRER Reg No:		
Reg No:		First Names:	First Names:		
Name:		Surname:	Surname:		
Address:		DOB:	Address:		
		Address:			
Fax Number:			Fax Number:		
Abiraterone acetate	Э				
Initial application Applications only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months. Prerequisites(tick boxes where appropriate) Patient has prostate cancer Patient has metastases and Patient's disease is castration resistant and Patient has disease progression (rising serum PSA) after second line anti-androgen therapy and Patient has ECOG performance score of 0-1 and Patient has not had prior treatment with taxane chemotherapy or Patient has ECOG performance score of 0-2 and Patient has not had prior treatment with abiraterone					
Renewal — abiraterone acetate					
Current approval Number (if known):					
Applications only from a medical oncologist, radiation oncologist, urologist or medical practitioner on the recommendation of a medical oncologist, radiation oncologist or urologist. Approvals valid for 6 months.					
Prerequisites(tick boxes where appropriate)					
Significant decrease in serum PSA from baseline					
and No evidence of clinical disease progression					
No initiation of taxane chemotherapy with abiraterone					
and The treatment remains appropriate and the patient is benefiting from treatment					

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2118 August 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:			
Reg No:	First Names:	First Names:			
Name:	Surname:	Surname:			
Address:	DOB:	Address:			
	Address:				
Fax Number:		Fax Number:			
Abiraterone acetate - continued					
Renewal — pandemic circumstances					
Current approval Number (if known):					
Applications from any relevant practitioner. Approvals valid for 6 months.					
Prerequisites(tick boxes where appropriate)					
The patient is clinically benefiting from treatment and continued treatment remains appropriate					
Abiraterone acetate to be discontinued at progression					
No initiation of taxane chemothera	No initiation of taxane chemotherapy with abiraterone				
	The regular Special Authority renewal requirements cannot be met due to COVID-19 constraints on the health sector				

I confirm the above details are correct and that in signing this form I understand I may be audited.